Additionally, antibody cross-reactivity between SARS-CoV-2 and other human coronaviruses (HCoVs) has implications for immune protection and the development of specific diagnostic tests.
Profiling of antibody responses using peptide microarrays has been proven to be a powerful approach to allow epitope-resolved identification of selective antigen binders.
In a recent publication using JPT’s RepliTope™ Antigen Collection Pan-Coronavirus peptide microarrays which display the whole SARS-CoV-2 proteome as well as relevant common cold corona virus antigens, a widespread cross-reactivity was detected across immunodominant antigen regions. Importantly, a statistically significant discrimination between COVID-19 patients and controls could be achieved allowing selection of dedicated peptides for further development.
Please contact us for further information on our variety of SARS-CoV-2 peptide microarrays and our related assay services!
We will be happy to discuss your project ideas in detail and evaluate on how we can support your studies.
Please contact us with any questions or comments.